Low-dose IL-2 therapy restores imbalance between Th17 and regulatory T cells in patients with the dermatomyositis combined with EBV/CMV viraemia.
Low-dose IL-2 therapy restores imbalance between Th17 and regulatory T cells in patients with the dermatomyositis combined with EBV/CMV viraemia.
复制标题
DOI：
10.1016/j.autrev.2022.103186
复制
发表时间：
2022-09
影响因子：
13.6
通讯作者：
Xinyu Zheng;R. Su;F. Hu;Yue Liu;Xiaofeng Li;Chong Gao;Caihong Wang
中科院分区：
文献类型：
--
作者：
Xinyu Zheng;R. Su;F. Hu;Yue Liu;Xiaofeng Li;Chong Gao;Caihong Wang
皮肌炎（DM）与感染密切相关，DM合并EB病毒（EBV）/巨细胞病毒（CMV）感染患者外周血淋巴细胞亚群水平研究较少。本研究旨在观察糖尿病合并EBV/CMV病毒血症患者外周血淋巴细胞亚群，尤其是Th 17调节性T细胞（Treg）的水平，并探讨短期小剂量IL-2对其的影响。方法34例糖尿病合并EBV/CMV病毒血症患者（糖尿病感染组），31例糖尿病无感染患者（糖尿病无感染组），20例健康对照。DM感染组13例，在常规治疗基础上加用小剂量IL-2 50万IU/d，5 d为1个疗程。结果感染组外周血总T细胞、总B细胞、NK细胞、CD 4 + T细胞及CD 4 + T细胞亚群（Th 1、Th 2、Th 17、Treg细胞）均明显降低。与健康对照组相比，感染组Th 17细胞明显减少，而非感染组Th 17细胞无明显减少（P> 0.001 vs.P= 0.171）。低剂量IL-2治疗后，Treg（P= 0.001）细胞和Th 17细胞水平显著升高，重新平衡了Th 17和Treg的比例.ConclusionsThe absolute numbers of Th 17 and Treg cells in DM patients with EBV/CMV viremia are further reduced.除了Treg细胞外，Th 17细胞的减少也可能是一个重要特征。小剂量IL-2治疗可能是一种有益且安全的前景免疫调节治疗，可恢复Th 17/Treg细胞失衡。低剂量IL-2治疗可能是一个新的前景领域，但仍存在一些挑战，如对各种病毒感染的长期免疫调节作用。
ObjectiveDermatomyositis (DM) is closely associated with infection, the levels of peripheral lymphocyte subpopulations are rarely studied in patients with DM combined with Epstein-Barr virus (EBV)/cytomegalovirus (CMV) infection. Here, we aimed to observe the level of lymphocyte subsets, especially Th17, regulatory T (Treg) cells in DM combined with EBV/CMV viremia, and explore the effects of short-term low-dose IL-2.Methods34 DM patients combined with EBV/CMV viremia (DM infection group), 31 DM patients without infection (DM non-infection group) and 20 healthy controls were entrolled in our study. In DM infection group, 13 patients received low-dose IL-2 at 0.50 Million IU/day for a five-day course on the basis of conventional treatment. All subjects had completed the decetion of the absolute numbers of lymphocytes subsets in peripheral blood by flow cytometry.ResultsThe infection group had significant decreases levels of total T, total B, NK, CD4 + T cells and CD4 + T subsets (Th1, Th2, Th17, Treg cells). Compare to the healthy controls, Th17 cells was significantly reduced in the infection group, but not in the non-infection group (P< 0.001 vs.P= 0.171). After low-dose IL-2 therapy, the levels of Treg (P= 0.001) cells and Th17 cells were significantly elevated, re-balancing the Th17 and Treg proportions.ConclusionsThe absolute numbers of Th17 and Treg cells in DM patients with EBV/CMV viremia is further reduced. In addition to Treg cells, a decrease in Th17 cells may be also a crucial feature. Low-dose IL-2 treatment may be beneficial and safe prospect immunomodulatory therapy to restores imbalance between Th17 and Treg cells for these patients. Low-dose IL-2 therapy may be a new prospect field with some challenges such as long-term immunoregulatory utility in various virus infection.